Drugs / GM-CSF
GM-CSF
English name Granulocyte Macrophage Colony Stimulating Factor
Trials 99 · started per year
today
1
3
4
2
7
4
7
5
4
3
3
2
3
3
3
5
3
9
3
3
3
7
5
2
2
2
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03189706 | Jun 2017 → Jun 2027 expected | neuroblastoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 121 trials · 1 met primary | ||||||
| Phase 1 | NCT04062721 | Aug 2025 → Nov 2028 expected | — | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT03982004 | Sep 2020 → Mar 2021 | breast cancer | Washington University School of Medicine | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03392545 | Apr 2018 → Apr 2020 | brain stem glioma, glioblastoma | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT03426995 | Mar 2018 → May 2019 | rheumatoid arthritis | GlaxoSmithKline | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02774421 | Jun 2017 → Feb 2025 overdue | posterior fossa ependymoma | University of Colorado, Denver | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02411786 | Aug 2015 → May 2019 | prostate cancer | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 1 | NCT02383212 | Feb 2015 → Nov 2019 | cancer | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01130376 | Sep 2009 → Oct 2011 | HIV infectious disease | Imperial College London | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00471471 | Oct 2008 → Dec 2011 | conjunctival cancer, cutaneous melanoma, ocular melanoma | Ahmad Tarhini | Completed | No outcome recorded |
| Phase 1 | NCT00631072 | Feb 2008 → Aug 2014 | melanoma | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00455221 | Feb 2008 → Dec 2010 | chronic myeloid leukemia | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 1 | NCT03014076 | Jan 2008 → Jan 2016 | breast cancer | Cancer Insight, LLC | Completed | No outcome recorded |
| Phase 1 | NCT00512889 | Aug 2007 → Feb 2011 | cutaneous melanoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00470015 | Mar 2007 → Apr 2009 | cutaneous melanoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00383994 | Sep 2006 → Jul 2019 | disease related to transplantation, leukemia, lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00111397 | May 2005 → Aug 2010 | Mycobacterium avium complex disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00600002 | Jun 2004 → Apr 2018 | pancreatic adenocarcinoma | Edward Nelson | Completed | No outcome recorded |
| Phase 1 | NCT00076037 | Apr 2004 → Jun 2006 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00952237 | Jan 2003 → Apr 2011 | Hodgkins lymphoma, leukemia, non-Hodgkin lymphoma, plasma cell myeloma | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00854789 | Dec 2002 → May 2012 | breast cancer | COL George Peoples, MD, FACS | Completed | Met primary |
| Phase 1 | NCT00001512 | Sep 1996 → Mar 2010 | follicular lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/29 trials | ||||||
| Phase 1/2 | NCT06345599 | May 2024 → Jan 2027 expected | pancreatic ductal adenocarcinoma | Second Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05131711 | Nov 2021 → Nov 2022 | glioblastoma | Beijing Tiantan Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04979832 | Sep 2021 → Dec 2023 | pouchitis | Zealand University Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04238819 | Nov 2020 → Mar 2024 | refractory malignant neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/2 | NCT03282188 | Oct 2017 → Jul 2018 | melanoma, skin cancer | University of Leeds | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01878565 | Jun 2013 → Dec 2014 | chronic hepatitis B virus infection | Beijing 302 Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT02009397 | Feb 2012 → Nov 2016 | metastatic melanoma | University of Louisville | Completed | No outcome recorded |
| Phase 1/2 | NCT01191034 | Aug 2010 → Aug 2012 | metastatic melanoma | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Terminated | No outcome recorded |
| Phase 1/2 | NCT01064375 | Dec 2009 → Mar 2012 | colorectal cancer | Maria Liljefors | Completed | No outcome recorded |
| Phase 251 trials · 1 met primary · 4 missed | ||||||
| Phase 2 | NCT06989333 | Jul 2025 → Jun 2027 expected | autoimmune pulmonary alveolar proteinosis | Jiuwu Bai | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06651853 | Oct 2024 → Dec 2027 expected | diffuse large B-cell lymphoma | The First Affiliated Hospital of Xiamen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06112041 | Oct 2023 → Oct 2026 expected | carcinoma | Second Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06472739 | Sep 2023 → Aug 2024 | — | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT05603013 | Oct 2022 → Jan 2024 | breast carcinoma, non-small cell lung carcinoma | Second Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 2 | NCT05760196 | Oct 2022 → Dec 2024 | — | Xiangpan Li | Unknown | No outcome recorded |
| Phase 2 | NCT05530200 | Sep 2022 → Dec 2024 | metastatic neoplasm | Second Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 2 | NCT05292417 | Mar 2022 → Mar 2023 | colorectal carcinoma | The First Affiliated Hospital of Xiamen University | Unknown | No outcome recorded |
| Phase 2 | NCT04909515 | Dec 2021 → Jun 2026 | neuroblastoma | Y-mAbs Therapeutics | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT04936529 | Aug 2021 → Jun 2027 expected | neuroblastoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04892498 | May 2021 → Aug 2023 | refractory malignant neoplasm | Second Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 2 | NCT04713371 | May 2021 → Dec 2024 | metastatic malignant neoplasm | Rampart Health, L.L.C. | Unknown | No outcome recorded |
| Phase 2 | NCT04739618 | Mar 2021 → Dec 2024 overdue | metastatic malignant neoplasm | ImmunSYS, LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06438614 | Aug 2020 → Jul 2023 | neuroblastoma, soft tissue neoplasm | Fundació Sant Joan de Déu | Completed | No outcome recorded |
| Phase 2 | NCT03927222 | Sep 2019 → Feb 2023 | glioblastoma | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | Terminated | No outcome recorded |
| Phase 2 | NCT04106180 | Sep 2019 → Aug 2022 | non-small cell lung carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT03304821 | Dec 2017 → Jul 2025 | peripheral arterial disease | Emory University | Completed | No outcome recorded |
| Phase 2 | NCT03222089 | Jul 2017 → Jul 2019 | metastatic malignant neoplasm in the colon | Fujian Cancer Hospital | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03033303 | Jan 2017 → Sep 2025 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT03316651 | Aug 2016 → Dec 2019 | autoimmune pulmonary alveolar proteinosis | Dai Huaping | Unknown | No outcome recorded |
| Phase 2 | NCT02728102 | Jul 2016 → Jun 2020 | plasma cell myeloma | National Heart, Lung, and Blood Institute (NHLBI) | Completed | Missed primary |
| Phase 2 | NCT02502786 | Jul 2015 → Jul 2026 overdue | osteosarcoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01530984 | Jun 2015 → Dec 2017 | prostate cancer | Lawrence Fong | Withdrawn | No outcome recorded |
| Phase 2 | NCT02243228 | Aug 2014 → Aug 2017 | autoimmune pulmonary alveolar proteinosis | Peking Union Medical College Hospital | Unknown | Missed primary |
| Phase 2 | NCT01903330 | Mar 2014 → Mar 2026 | gliosarcoma | Epitopoietic Research Corporation | Unknown | No outcome recorded |
| Phase 2 | NCT01909752 | Jul 2013 → Nov 2016 | non-small cell lung carcinoma | UbiVac | Completed | No outcome recorded |
| Phase 2 | NCT01542684 | Mar 2012 → Apr 2013 | leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01183884 | Aug 2010 → Nov 2018 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01094496 | Apr 2010 → Jul 2011 | urinary bladder cancer | Celldex Therapeutics | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00488982 | Apr 2007 → Mar 2014 | prostate cancer | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT00548847 | Jan 2007 → Mar 2015 | leukemia | Emory University | Completed | No outcome recorded |
| Phase 2 | NCT00455897 | Dec 2006 → Nov 2007 | diffuse large B-cell lymphoma | Massachusetts General Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00450008 | Dec 2006 → Aug 2008 | prostate neoplasm | The Methodist Hospital Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT00477087 | Jul 2006 → Oct 2009 | prostate neoplasm | Stanford University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00447473 | Jul 2006 → Aug 2008 | prostate neoplasm | The Methodist Hospital Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT00448409 | May 2006 → Apr 2007 | prostate neoplasm | The Methodist Hospital Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00274287 | Jan 2006 → Dec 2010 | prostate cancer | Oncology Specialists, S.C. | Completed | No outcome recorded |
| Phase 2 | NCT00252915 | Nov 2005 → Jan 2007 | infectious disease with sepsis | Charite University, Berlin, Germany | Completed | Met primary |
| Phase 2 | NCT00254592 | Oct 2005 → Sep 2013 | breast cancer | University of California, Irvine | Completed | No outcome recorded |
| Phase 2 | NCT00940342 | Oct 2004 → Jan 2017 | leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00661622 | Oct 2004 → Dec 2011 | uveal melanoma | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 2 | NCT00201409 | Jul 2004 → May 2009 | adult acute respiratory distress syndrome | University of Michigan | Completed | Missed primary |
| Phase 2 | NCT01176552 | May 2004 → Sep 2008 | renal cell carcinoma | Kidney Cancer Research Bureau | Completed | No outcome recorded |
| Phase 2 | NCT00499343 | Jan 2004 → Oct 2008 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00257322 | Apr 2003 → Jan 2007 | colon carcinoma, rectal cancer | University of California, Irvine | Completed | No outcome recorded |
| Phase 2 | NCT00429104 | Aug 2002 → Nov 2009 | breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00090870 | Apr 2002 → Mar 2010 | kidney cancer | Medical University of South Carolina | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00582725 | Mar 2002 → Dec 2005 | diffuse large B-cell lymphoma | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 2 | NCT01939730 | Aug 1999 → Dec 2006 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00678054 | Apr 1999 → Aug 2000 | prostate cancer | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT00272493 | ? → Nov 2007 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 35 trials · 1 met primary · 2 missed | ||||||
| Phase 3 | NCT05232916 | Aug 2022 → Dec 2026 expected | breast cancer | Greenwich LifeSciences, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT01715974 | Dec 2017 → Jul 2022 | pregnancy loss, recurrent, 4 | Centre for Endocrinology and Reproductive Medicine, Italy | Unknown | Met primary |
| Phase 3 | NCT03023111 | Jun 2017 → Aug 2019 | cutaneous leishmaniasis | Hospital Universitário Professor Edgard Santos | Completed | Missed primary |
| Phase 3 | NCT01322490 | Nov 2011 → Sep 2017 | metastatic prostate carcinoma | Bavarian Nordic | Completed | Missed primary |
| Phase 3 | NCT00880243 | Mar 1999 → Sep 2006 | acute myeloid leukemia | Acute Leukemia French Association | Completed | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT03769844 | Dec 2018 → Dec 2023 | multiple organ dysfunction syndrome | Nationwide Children's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02933333 | Sep 2016 → Aug 2020 | acute lymphoblastic leukemia, acute myeloid leukemia, hepatoblastoma, neuroblastoma +1 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT02451488 | May 2015 → Nov 2016 | cutaneous melanoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT02250768 | Jul 2013 → Mar 2014 | infertility disorder | Vietnam National University | Completed | No outcome recorded |
| Phase 4 | NCT01718210 | Dec 2012 → Dec 2015 | infertility disorder | Centre for Endocrinology and Reproductive Medicine, Italy | Completed | No outcome recorded |
| Phase 4 | NCT01495637 | Dec 2011 → Feb 2022 | brain injury | Mark Hall | Completed | No outcome recorded |
| Phase 4 | NCT01232504 | Sep 2009 → Mar 2013 | fungal infectious disease | Xiamen Amoytop Biotech Co., Ltd. | Completed | Mixed |
| Phase 4 | NCT00979706 | Mar 2005 → Nov 2014 | HIV infectious disease | Juan A. Arnaiz | Completed | No outcome recorded |
| Phase not applicable3 trials · 1 missed | ||||||
| — | NCT04100655 | Oct 2019 → Jun 2020 | uterine disorder | Sir Run Run Shaw Hospital | Unknown | No outcome recorded |
| — | NCT05451420 | Dec 2017 → Jun 2020 | chronic hepatitis B virus infection | Henan Provincial People's Hospital | Completed | Missed primary |
| — | NCT02100930 | Mar 2014 → Mar 2019 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04501757 | — | neuroblastoma | Memorial Sloan Kettering Cancer Center | No longer available | No outcome recorded |
| Comparator or background therapy105 trials | ||||||
| Phase 1 | NCT05544968 Background | Mar 2026 → Jan 2028 expected | Hodgkins lymphoma, anaplastic large cell lymphoma, diffuse large B-cell lymphoma, large-cell immunoblastic lymphoma +2 | Medical College of Wisconsin | Recruiting | No outcome recorded |
| Phase 1 | NCT07374029 Background | Feb 2026 → Oct 2027 expected | acute myeloid leukemia | David Avigan | Recruiting | No outcome recorded |
| Phase 1 | NCT07377435 Background | Jan 2026 → Mar 2028 expected | plasma cell myeloma, refractory plasma cell neoplasm | David Avigan | Recruiting | No outcome recorded |
| Phase 1 | NCT06514898 Background | May 2025 → Sep 2027 expected | medulloblastoma non-WNT/non-SHH group 3, medulloblastoma non-WNT/non-SHH group 4 | University of Florida | Recruiting | No outcome recorded |
| Phase 1 | NCT06799026 Background | Jan 2025 → Sep 2028 expected | plasma cell myeloma | David Avigan | Recruiting | No outcome recorded |
| Phase 1 | NCT06254326 Background | Sep 2024 → Dec 2027 expected | oligodendroglioma | University of Florida | Recruiting | No outcome recorded |
| Phase 1 | NCT05238558 Background | Jan → Oct 2022 | colorectal cancer | Hubro Therapeutics AS | Completed | No outcome recorded |
| Phase 1 | NCT04963413 Background | Jan 2022 → Sep 2023 | glioblastoma | University of Florida | Terminated | No outcome recorded |
| Phase 1 | NCT05307835 Background | Dec 2021 → Jun 2026 overdue | esophageal cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04861948 Background | May 2021 → Jul 2022 | lung adenocarcinoma, osteosarcoma | Innovent Biologics (Suzhou) Co. Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT03743298 Background | Apr 2021 → May 2024 | metastatic melanoma | Aivita Biomedical, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT04810910 Background | Mar 2021 → Mar 2025 | pancreatic exocrine neoplasm | Zhejiang Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT07504484 Background | Oct 2020 → Dec 2023 | colorectal cancer, non-small cell lung carcinoma | Ying Yuan, MD | Completed | No outcome recorded |
| Phase 1 | NCT04270149 Background | Sep 2020 → May 2025 overdue | breast cancer | Herbert Lyerly | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03615404 Background | Oct 2018 → Nov 2019 | brain cancer, glioblastoma, medulloblastoma | Gary Archer Ph.D. | Completed | No outcome recorded |
| Phase 1 | NCT03334305 Background | Aug 2018 → Mar 2025 | high grade astrocytic tumor | University of Florida | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03396575 Background | Jul 2018 → Mar 2025 | diffuse intrinsic pontine glioma | University of Florida | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03538314 Background | Jul 2018 → Oct 2022 | melanoma | Ultimovacs ASA | Completed | No outcome recorded |
| Phase 1 | NCT03645148 Background | Oct 2017 → Nov 2020 | exocrine pancreatic carcinoma | Zhejiang Provincial People's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02130869 Background | Oct 2014 → Dec 2017 | lymphoma, neuroblastoma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02149225 Background | Oct 2014 → Jun 2018 | glioblastoma | Immatics Biotechnologies GmbH | Completed | No outcome recorded |
| Phase 1 | NCT02019524 Background | Sep 2013 → Dec 2016 | breast cancer, ovarian cancer | COL George Peoples, MD, FACS | Completed | No outcome recorded |
| Phase 1 | NCT01403285 Background | Aug 2011 → Apr 2014 | glioblastoma | Immatics Biotechnologies GmbH | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01022255 Background | Jan 2010 → Oct 2013 | follicular lymphoma | Icon Genetics GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00850785 Background | Jan 2009 → May 2012 | non-small cell lung carcinoma | Providence Health & Services | Completed | No outcome recorded |
| Phase 1 | NCT00561275 Background | Oct 2007 → May 2008 | esophageal cancer | Japanese Foundation for Cancer Research | Completed | No outcome recorded |
| Phase 1 | NCT00834665 Background | Dec 2006 → Dec 2017 | plasma cell myeloma | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1 | NCT00374049 Background | Jun 2006 → Jan 2008 | prostate cancer | Olivera Finn | Completed | No outcome recorded |
| Phase 1 | NCT00841399 Background | Jul 2001 → Sep 2012 | breast cancer | COL George Peoples, MD, FACS | Completed | No outcome recorded |
| Phase 1/2 | NCT06173219 Background | Aug 2025 → Jul 2026 overdue | neoplasm | China-Japan Friendship Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06934538 Background | Jun 2025 → Jun 2028 expected | colorectal cancer | Brenus Pharma | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04929652 Background | Jun 2021 → Jun 2022 | colorectal cancer | Jiangsu Cancer Institute & Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT03761914 Background | Sep 2019 → Jul 2022 | acute myeloid leukemia, colorectal cancer, ovarian cancer, small cell lung carcinoma +1 | Sellas Life Sciences Group | Completed | No outcome recorded |
| Phase 1/2 | NCT02709993 Background | Jul 2017 → Oct 2020 | cancer, hematopoietic and lymphoid cell neoplasm | Kiromic BioPharma Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT02223312 Background | Jul 2017 → Oct 2018 | cancer, hematopoietic and lymphoid cell neoplasm | Kiromic BioPharma Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT02705703 Background | Jul 2017 → Oct 2018 | metastatic malignant neoplasm | Kiromic BioPharma Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT03559413 Background | Jun 2016 → Mar 2022 | childhood acute lymphoblastic leukemia | University Children's Hospital Tuebingen | Completed | No outcome recorded |
| Phase 1/2 | NCT02275416 Background | Feb 2015 → Oct 2016 | melanoma | Ultimovacs ASA | Completed | No outcome recorded |
| Phase 1/2 | NCT02173093 Background | Nov 2014 → Dec 2019 | neuroblastoma | University of Virginia | Unknown | No outcome recorded |
| Phase 1/2 | NCT02078648 Background | May 2014 → Sep 2017 | adult glioblastoma | Stemline Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01784913 Background | Apr 2013 → Jul 2015 | prostate cancer | Ultimovacs ASA | Completed | No outcome recorded |
| Phase 1/2 | NCT01789099 Background | Apr 2013 → Feb 2016 | non-small cell lung carcinoma | Ultimovacs ASA | Completed | No outcome recorded |
| Phase 1/2 | NCT01827137 Background | Apr 2013 → Dec 2016 | plasma cell myeloma | Sellas Life Sciences Group | Completed | No outcome recorded |
| Phase 1/2 | NCT02261714 Background | Dec 2012 → May 2019 | pancreatic adenocarcinoma | Targovax ASA | Completed | No outcome recorded |
| Phase 1/2 | NCT01757626 Background | Dec 2012 → Dec 2026 expected | neuroblastoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT01627678 Background | Sep 2012 → Nov 2013 | HIV infectious disease | Bionor Immuno AS | Completed | Met primary |
| Phase 1/2 | NCT01580696 Background | Apr 2012 → Jul 2016 | endometrial cancer, fallopian tube cancer, ovarian cancer, peritoneum cancer | COL George Peoples, MD, FACS | Completed | No outcome recorded |
| Phase 1/2 | NCT01081223 Background | Apr 2010 → Mar 2011 | glioblastoma | TVAX Biomedical | Completed | No outcome recorded |
| Phase 1/2 | NCT00204516 Background | Apr 2007 → Aug 2011 | melanoma | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 1/2 | NCT00302861 Background | Mar 2006 → ? | B-cell chronic lymphocytic leukemia | Genitope Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT00204607 Background | Jul 2004 → Jan 2007 | melanoma | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 1/2 | NCT00089219 Background | Jul 2003 → May 2006 | cutaneous melanoma, ocular melanoma | University of Virginia | Completed | No outcome recorded |
| Phase 2 | NCT05479045 Background | Sep 2026 → Nov 2027 expected | ovarian carcinoma, uterine adnexa cancer | Georgetown University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07537400 Background | May 2026 → Jun 2028 expected | neuroblastoma | Shaare Zedek Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07327411 Background | Dec 2025 → Feb 2027 expected | refractory malignant neoplasm | Second Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06450041 Background | Dec 2024 → Dec 2028 expected | neuroblastoma | New Approaches to Neuroblastoma Therapy Consortium | Recruiting | No outcome recorded |
| Phase 2 | NCT06013618 Background | Jun 2023 → Dec 2026 expected | neuroblastoma | Sun Yat-sen University Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05115500 Background | Nov 2021 → Oct 2024 | carcinoma | Second Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 2 | NCT03782064 Background | Feb 2019 → Jan 2021 | plasma cell myeloma | Beth Israel Deaconess Medical Center | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT03600350 Background | Sep 2018 → Nov 2022 overdue | prostate cancer | University of Wisconsin, Madison | Active not recruiting | Missed primary |
| Phase 2 | NCT03630211 Background | Jul 2018 → Aug 2026 overdue | diffuse scleroderma, interstitial lung disease, pulmonary hypertension | Paul Szabolcs | Recruiting | No outcome recorded |
| Phase 2 | NCT03363373 Background | Apr 2018 → Jun 2026 overdue | neuroblastoma | Y-mAbs Therapeutics | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02978222 Comparator | Jul 2017 → Jan 2020 | ovarian cancer | Marker Therapeutics, Inc. | Terminated | Missed primary |
| Phase 2 | NCT02465268 Background | Aug 2016 → Nov 2023 | astrocytoma (excluding glioblastoma), glioblastoma | University of Florida | Completed | Missed primary |
| Phase 2 | NCT02677155 Background | Jan 2016 → Feb 2021 | follicular lymphoma | Oslo University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02641782 Background | Nov 2015 → Dec 2016 | neuroblastoma | University of Cologne | Terminated | No outcome recorded |
| Phase 2 | NCT02297698 Background | Oct 2014 → Dec 2021 | breast cancer | Cancer Insight, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01857934 Background | Jul 2013 → Oct 2021 | neuroblastoma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01570036 Background | May 2013 → Sep 2018 | breast cancer | George E. Peoples | Completed | No outcome recorded |
| Phase 2 | NCT01543464 Background | May 2012 → Sep 2016 | melanoma | Inge Marie Svane | Terminated | No outcome recorded |
| Phase 2 | NCT01498328 Background | Dec 2011 → Apr 2015 | giant cell glioblastoma, gliosarcoma | Celldex Therapeutics | Completed | Missed primary |
| Phase 2 | NCT01049854 Background | Sep 2011 → Nov 2017 | beta thalassemia, bone marrow failure syndrome, histiocytosis, immunodeficiency disease +4 | New York Medical College | Completed | No outcome recorded |
| Phase 2 | NCT01245673 Background | May 2011 → Dec 2015 | plasma cell myeloma | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT01266083 Background | Jan 2011 → Sep 2016 | acute lymphoblastic leukemia, acute myeloid leukemia | Sellas Life Sciences Group | Completed | Met primary |
| Phase 2 | NCT01183897 Background | Aug 2010 → Sep 2018 | neuroblastoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01174082 Background | Jul 2010 → Feb 2017 | plasma cell myeloma | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00799110 Background | Aug 2008 → Dec 2024 | fallopian tube cancer, ovarian cancer, peritoneum cancer | Beth Israel Deaconess Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT00646763 Comparator | Apr 2008 → Sep 2009 | — | Emory University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00610389 Background | Feb 2008 → Apr 2010 | hepatocellular carcinoma, melanoma, renal cell carcinoma | Clinica Universidad de Navarra, Universidad de Navarra | Unknown | No outcome recorded |
| Phase 2 | NCT00530140 Background | Oct 2007 → Sep 2013 | follicular lymphoma | Clinica Universidad de Navarra, Universidad de Navarra | Unknown | No outcome recorded |
| Phase 2 | NCT00488592 Background | Jun 2007 → Apr 2010 | acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00446173 Background | Mar 2007 → Jan 2009 | leukemia | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00415857 Background | Dec 2006 → Sep 2013 | leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00256243 Background | Apr 2004 → Mar 2011 | breast cancer | Rita Sanghvi, Mehta | Completed | No outcome recorded |
| Phase 2 | NCT00505921 Background | Mar 2003 → Nov 2009 | lymphoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00533923 Background | Dec 2002 → Jan 2007 | Hodgkins lymphoma, acute myeloid leukemia, aplastic anemia, chronic lymphocytic leukemia/small lymphocytic lymphoma +2 | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00208949 Comparator | Sep 2002 → May 2010 | hematologic disorder | Emory University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00208975 Comparator | Jul 2002 → Dec 2009 | lymphoma | Emory University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00948480 Background | Oct 2000 → Sep 2007 | metastatic melanoma | Hoag Memorial Hospital Presbyterian | Completed | No outcome recorded |
| Phase 2 | NCT00005780 Background | Jun 2000 → Jun 2021 | mantle cell lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00001564 Background | Dec 1996 → Oct 2007 | Ewing sarcoma, rhabdomyosarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2/3 | NCT00090493 Background | Jun 2004 → Jul 2007 | plasma cell myeloma | University of Arkansas | Completed | No outcome recorded |
| Phase 3 | NCT05266001 Comparator | Jun 2022 → Sep 2025 | multiple organ dysfunction syndrome | Nationwide Children's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT04229979 Background | Feb 2021 → Dec 2025 overdue | acute myeloid leukemia | Sellas Life Sciences Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01875653 Background | Oct 2014 → Jan 2016 | melanoma | Lisata Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT01480479 Background | Nov 2011 → Nov 2016 | giant cell glioblastoma, gliosarcoma, mixed astrocytoma-ependymoma-oligodendroglioma | Celldex Therapeutics | Completed | Missed primary |
| Phase 3 | NCT01265901 Background | Dec 2010 → Jul 2015 | renal cell carcinoma | Immatics Biotechnologies GmbH | Completed | Missed primary |
| Phase 3 | NCT00769704 Comparator | Apr 2009 → Feb 2013 | melanoma | BioVex Limited | Completed | Met primary |
| Phase 3 | NCT00091676 Background | Jan 2000 → Dec 2012 | non-Hodgkin lymphoma | Biovest International | Unknown | Mixed |
| Phase 3 | NCT00001561 Background | Nov 1996 → Sep 2005 | graft versus host disease, plasma cell myeloma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 4 | NCT06047535 Background | Oct 2023 → Jun 2027 expected | neuroblastoma | SciClone Pharmaceuticals | Not yet recruiting | No outcome recorded |
| — | NCT01828762 Background | Dec 2012 → Dec 2013 | hepatocellular carcinoma | Shanghai AbelZeta Ltd. | Completed | No outcome recorded |
| — | NCT01374711 Comparator | May → Nov 2011 | infectious disease with sepsis, multiple organ dysfunction syndrome | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT00912574 Comparator | Jun 2004 → Jul 2008 | melanoma | University of Virginia | Completed | No outcome recorded |
| — | NCT00912418 Background | May 2000 → Sep 2002 | melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
Press releases naming this drug 34 releases
Evidence & citations 24 cited values
Every value below carries the sentence it was read from. 218 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GM CSF | “This treatment will combine peritumoral injection of IL-2, IFN-α and GM-CSF (6000 IU, 100.000 IU and 300 ng per tumor injected, respectively), as well as topical application of...” NCT01191034 ↗205“multiple peptide cocktail including LY6K and vascular endothelial growth factor receptor 1 (VEGFR1) and vascular endothelial growth factor receptor 2 (VEGFR2) together with IFA...” NCT00561275 ↗ “Personalized anti-tumor neoantigen injection (300 μg/peptide) plus GM-CSF (40 μg per injection site) will be administered via subcutaneous injection at multiple sites (around...” NCT07504484 ↗ “Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First...” NCT06047535 ↗ “In a separate trial, GMCSF was used in breast cancer patients treated with adriamycin based chemotherapy as the preferred growth factor in a neoadjuvant setting (16).” NCT00256243 ↗ “STC-1010 administered with immunostimulants (IS) in low-dose (cyclophosphamide and GM-CSF) and standard of care (SOC) therapy (mFOLFOX6 with or without bevacizumab)” NCT06934538 ↗ “100 micrograms (mcg) granulocyte-macrophage colony-stimulating factor (GM-CSF) and 1 milliliter (mL) of Montanide ISA-51 adjuvant.” NCT05479045 ↗ “At the time of vaccine administration, one vial of frozen suspended peptide is thawed and mixed with 250mcg GM-CSF in the syringe.” NCT02019524 ↗ “Each dose of DC-TC contains approximately 10-20 million cells. Each dose is suspended in 500 mcg GM-CSF prior to administration.” NCT01875653 ↗ “AV-MEL-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.” NCT03743298 ↗ “Each DRibble vaccine will be followed by the 6-day infusion of GM-CSF via the CADD-MS 3 pump (50 micrograms/24 hrs).” NCT00850785 ↗ |
| Known as | GM-CSF (sargramostim) | “GM-CSF (sargramostim)” NCT01580696 ↗1“GM-CSF (Sargramostim)” NCT02019524 ↗ |
| Known as | GM-CSF = Leukine | “GM-CSF = Leukine” NCT01627678 ↗ |
| Known as | GM-CSF: molgramostim | “GM-CSF: molgramostim” NCT00880243 ↗ |
| Known as | granulocyte and macrophage colony-stimulating factor | “topical granulocyte and macrophage colony-stimulating factor (GM-CSF) and miltefosine (G + M) versus placebo and miltefosine (P + M)” PMID 33253864 ↗ Nov 2020 |
| Known as | granulocyte macrophage colony- stimulating factor (GM-CSF) | “granulocyte macrophage colony- stimulating factor (GM-CSF)” NCT00488592 ↗1“Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)” NCT07537400 ↗ |
| Known as | granulocyte macrophage stimulating factor | “Granulocyte-macrophage stimulating factor (GM-CSF) increases circulating dendritic cells but does not abrogate suppression of adaptive cellular immunity” PMID 22270330 ↗ Jan 20121“granulocyte macrophage stimulating factor (GM-CSF)” NCT05451420 ↗ |
| Known as | Granulocyte-macrophage colony-stimulating factor | “Through compassionate use, 4 patients with progression of disease or refractory disease after HITS therapy, have been further treated with two cycles of a combination of...” NCT06438614 ↗43“The primary goal of this study is to determine the effects (good and bad) of Granulocyte-macrophage colony stimulating factor (GM-CSF) in combination with Cytoxan, Adriamycin,...” NCT00455897 ↗ “Although IFN-γ and granulocyte-macrophage colony-stimulating factor (GM-CSF) restore immune competence of ex vivo stimulated leukocytes of patients with sepsis, effects on...” PMID 22822024 ↗ Jul 2012 “Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a naturally occurring substance that is made by the body in response to infection or inflammation, and greatly...” NCT00272493 ↗ “Their phase 1-2 trials revealed that the E75 + granulocyte-macrophage colony-stimulating factor (GM-CSF) vaccine is safe and effective in stimulating clonal expansion of...” PMID 20845479 ↗ Sep 2010 “The purpose of this study is to find out if an antibody called Humanized 3F8 (Hu3F8) combined with granulocyte- macrophage colony stimulating factor (GM-CSF) is safe for...” NCT01757626 ↗ “PRaG therapy, which combines PD-1/PD-L1 inhibitors, radiotherapy, and granulocyte-macrophage colony-stimulating factor (GM-CSF), aims to treat patients with advanced, refractory tumors.” PMID 41308040 ↗ Nov 2025 “Granulocyte macrophage colony-stimulating factor (GM-CSF) was administered at a dose of 125 μg/m²/day subcutaneously for 14 days, followed by a 14-day rest period for 24 weeks.” NCT00769704 ↗ “three (3) days of subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) to increase bone marrow production of monocytes and dendritic cell (DC) precursors” NCT02705703 ↗ “Treatment of autoimmune pulmonary alveolar proteinosis (aPAP) by inhaled granulocyte-macrophage colony stimulating factor (GM-CSF) is considered safe and effective.” PMID 32615994 ↗ Jul 2020 “Administration of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) to patients with pancreatic adenocarcinoma will result in enhance recruitment of DCs” NCT00600002 ↗ |
| Known as | Granulocyte-Macrophage Stimulating-Colony Factor | “The purpose of this study was to investigate the potential effects of Granulocyte-Macrophage Stimulating-Colony Factor (GM-CSF) supplementation in embryo culture for patients...” NCT02250768 ↗ |
| Known as | granulocyte-monocyte colony-stimulating factor | “granulocyte-monocyte colony-stimulating factor (GM-CSF)” PMID 21632504 ↗ May 2011 |
| Known as | Leucomax | “GM-CSF (Leucomax, recombinant human GM-CSF from Escherichia Coli, Schering Plough, Kenilworth,N.J., USA) is given at a dose of 5µg/kg per day, intravenously beginning at day 1...” NCT00880243 ↗ |
| Known as | Leukine | “Interferon gamma 1b (Actimmune) and GM-CSF (Leukine) are two cytokine therapies that have been approved in the treatment of chronic granulomatous disease and...” NCT00111397 ↗1“CDX-110 with sargramostim (GM-CSF) (Leukine®)” NCT01480479 ↗ |
| Known as | Molgramostim | “GM-CSF (Molgramostim, TOPLEUCON®; Xiamen Amoytop Biotech Co., Ltd., China)” NCT01232504 ↗ |
| Known as | NSC-613795 | “GM-CSF Granulocyte-Macrophage Colony-Stimulating Factor (Hoechst/Immunex), NSC-613795” NCT00001561 ↗ |
| Known as | Recombinant human GM-CSF | “Recombinant human GM-CSF” NCT02411786 ↗ |
| Known as | Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor | “GM-CSF (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor) The dose and duration of GM-CSF (7.5 mcg/kg/day) was selected.” NCT00952237 ↗ |
| Known as | rhGM-CSF | “Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF)” NCT01232504 ↗ |
| Known as | rhu GM-CSF | “GM-CSF is a recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF) produced by recombinant DNA technology in a yeast (S. cerevisiae) expression system.” NCT03282188 ↗ |
| Known as | sangramostim | “PURPOSE: To determine the biologic effect of granulocyte-macrophage colony-stimulating factor (sangramostim, GM-CSF; Immunex Corporation, Seattle, WA) as measured by...” PMID 12506177 ↗ Jan 2003 |
| Known as | sargramostim | “GM-CSF (granulocyte-macrophage colony stimulating factor, also called sargramostim, GM, or Leukine), a growth factor” NCT00208975 ↗4“GM-CSF (Sargramostim) was co administered with each vaccine dose.” NCT00488592 ↗ “CDX-110 with sargramostim (GM-CSF) (Leukine®)” NCT01480479 ↗ “sargramostim (GM-CSF) SC on days 1-10” NCT00090870 ↗ “GM-CSF (also called sargramostim)” NCT02100930 ↗ |
| Known as | Topleucon | “Topleucon®” NCT01232504 ↗ |
| Action | Activate | “GM-CSF reverses monocyte deactivation” PMID 19590022 ↗ Jul 2009 |
| Modality | Protein / enzyme biologic | “granulocyte-monocyte colony-stimulating factor (GM-CSF)” PMID 21632504 ↗ May 2011 |
| Route | Subcutaneous | “GM-CSF is administered subcutaneously locally with the vaccine” NCT00001512 ↗ |